Modulation of the innate immune response during respiratory tract infections
Both the growing number of immunocompromised patients susceptible to pneumonia, and the widespread use of antibiotics that has led to a rise of antibiotic resistance among microorganisms, have made the treatment of pneumonia more difficult. Hence, there is a need for novel therapeutic approaches for respiratory tract infections. Immunotherapy, aimed at modulating the immune response, may serve as an important adjuvant to antibiotic therapy in the treatment of infectious diseases. However, before immunomodulation can become a serious tool in the treatment of severe pneumonia, knowledge of the pulmonary host defense needs to increase.
KeywordsTumor Necrosis Factor Alpha Innate Immune Response Severe Pneumonia Pneumococcal Pneumonia Infectious Focus
Unable to display preview. Download preview PDF.
- 14.Beutler B (1995) TNF, immunity and inflammatory disease: lessons of the past decade. J Invest Med 43:227–235Google Scholar
- 17.Oswald IP, Wynn TA, Sher A, James SL (1992) Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor alpha required as a costimulatory factor for interferon gamma-induced activation. Proc Natl Acad Sci USA 89:8676–8680PubMedCrossRefGoogle Scholar
- 29.Abraham E, Wunderink R, Silverman H, et al (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 273:934–941PubMedCrossRefGoogle Scholar
- 32.Schultz M, Rijneveld A, Florquin S, et al (2002) The role of interleukin-1 in the pulmonary immune response during Pseudomonas aeruginosa pneumonia. Am J Physiol 282:285–290Google Scholar